Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

New data confirm the benefit of deep brain stimulation to treat obsessive-compulsive disorders

Published on: 13/10/2020 Reading time: 1 min
cerveau

A study by researchers and clinicians from the Paris Brain Institute (Inserm/CNRS/Sorbonne University) and AP-HP (Henri Mondor and Pitié-Salpêtrière Hospitals) confirms the beneficial effect of deep brain stimulation on several brain structures in severe obsessive-compulsive disorders that are resistant to drug treatment. The results are published in the journal Biological Psychiatry.

For more than 10 years, deep brain stimulation has been a source of hope for the treatment of obsessive compulsive disorders (OCD), considered one of the most disabling disorders by the WHO. OCD is associated with more years of lost years due to disability than multiple sclerosis and Parkinson's disease combined. It manifests itself in 2 main categories of symptoms: obsessions in the form of thoughts, images with unpleasant content that are involuntarily imposed on the subject. These obsessions generate major anxiety and require the person to perform repeated behaviors and rituals to try to calm these distressing ideas.

Cognitive-behavioural psychotherapy (CBT) and/or serotonergic antidepressants prescribed in high doses to achieve an anti-OCD effect, improve the symptoms of two-thirds of patients. For the remaining third, therapeutic strategies involve complex combinations of treatments, and for a part of them, deep brain stimulation (DBS) represents a real therapeutic perspective.

In a new study, published in the journal Biological Psychiatry, researchers and clinicians from the Paris Brain Institute analyzed the effects of DBS on three brain structures, the subthalamic nucleus, the accumbens nucleus and the caudate nucleus, in 8 patients with severe OCD resistant to all available treatments. This is the first study comparing the effect of DBS on three distinct targets in the brain in the same patients.

Their results show an almost equivalent reduction in symptoms regardless of the structure stimulated after 3 months of stimulation, but the majority of patients expressed a subjective preference for the stimulation of a region of the subthalamic nucleus, without knowing that it was this structure that was targeted. They also highlight the possibility of identifying early predictors of response to long-term subthalamic nucleus stimulation.

"Consistent with our previous results*, we also observed a significant improvement of symptoms in longer-term in 3 patients responding to subthalamic nucleus stimulation and a partial response in another 3 patients. This suggests that the most beneficial effects of DBS may be delayed and that this should be taken into account in patient follow-up. The "blinded" choice of patients for this target also shows the interest in taking into account clinical dimensions that go beyond the usual quantitative clinical evaluations to assess a therapeutic effect. "explains Luc Mallet, Professor of Psychiatry at the University of Paris Est Créteil and researcher at the Paris Brain Institute.

The present study confirms the benefit of stimulating different deep brain structures in patients with severe obsessive-compulsive disorders that are resistant to other available treatments, underlining the interest of precisely identifying the neural networks underlying these disorders. Research is still needed to identify precise characteristics that predict whether or not patients will respond to deep brain stimulation.

* Mallet, L., Du Montcel, S. T., Clair, A.-H., Arbus, C., Bardinet, E., Baup, N., Chabardès, S., Chéreau, I., Czernecki, V., Fontaine, D., Harika-Germaneau, G., Haynes, W. I., Houeto, J.-L., Jaafari, N., Krack, P., Millet, B., Navarro, S., Polosan, M., Pelissolo, A. and Welter, M.-L. (2019) ‘Long-term effects of subthalamic stimulation in Obsessive-Compulsive Disorder: Follow-up of a randomized controlled trial’, Brain Stimulation, 12(4), 1080-1082.

Sources

https://pubmed.ncbi.nlm.nih.gov/33012521/
Welter ML, Alves Dos Santos JF, Clair AH, Lau B, Diallo HM, Fernandez-Vidal S, Belaid H, Pelissolo A, Domenech P, Karachi C, Mallet L. Biol Psychiatry. 2020 Oct 2

Our news on the subject

À la recherche de marqueurs d’imagerie dans la démence frontotemporale
Searching for Imaging Markers in Frontotemporal Dementia
Could exploring the relationships between different brain networks help us understand frontotemporal dementia (FTD)? This neurodegenerative disease, which progresses at varying rates, is often diagnosed late—when clinical signs are already severe. At...
01.07.2025 Research, science & health
Monocyte – un globule blanc qui se différencie en macrophage. Crédit : Université d’Edinbourg.
Discovery of a Macrophage Anomaly in Multiple Sclerosis
Certain patients with multiple sclerosis (MS) can partially regenerate myelin—the protective sheath that surrounds nerve fibers—which is damaged during the evolution of the disease. In studying how immune cells influence this remyelination...
12.19.2024 Research, science & health
Interneurones. Crédit : UCLA Broad Stem Cell Research Center.
Stimulating specific neurons in the striatum stops compulsive behaviour
What if we could resist compulsions? These irrational behaviours, particularly common in obsessive-compulsive disorder (OCD), are hard to suppress. At Paris Brain Institute, Éric Burguière's team shows that we can anticipate them and block them...
09.10.2024 Research, science & health
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.
Ultrasound show unexpected effects on motor neuron disease
Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain...
09.05.2024 Research, science & health
Un neurone
Rett syndrome: a new gene therapy on the way
Gene therapy could be our best chance of treating Rett syndrome, a neurological disorder that causes severe intellectual and motor impairments. At Paris Brain Institute, Françoise Piguet and her colleagues have looked closely at brain cholesterol...
07.16.2024 Research, science & health
Lésions d’un patient à l’inclusion dans le protocole (M0) disparues après 2 ans de traitement à la Leriglitazone (M24)
The dual effect of leriglitazone in X-linked Adrenoleukodystrophy (X-ALD)
In 2023, the team led by Professor Fanny Mochel (AP-HP, Sorbonne University), a Paris brain Institute researcher, showed that daily dose of leriglitazone slow down the progression of myelopathy in patients with X-linked adrenoleukodystrophy, and...
06.28.2024 Research, science & health
See all our news